| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
Luteolinidin Chloride targets CD38 (Ki = 11.4 μM), NADPH oxidase, and tyrosinase (IC50 = 3.7 μM). It functions as a CD38 inhibitor and a competitive inhibitor of tyrosinase.
|
|---|---|
| ln Vitro |
In isolated rat hearts, Luteolinidin Chloride (5-50 μM; 20 min) dose-dependently maintains total coronary blood flow and NOS-dependent coronary blood flow after ischemia. At 25 μM, it restores NADP(H) and NAD(H) levels to near pre-ischemic levels. At 50 μM, it partially preserves BH4 levels, reduces infarct size, and decreases acetylcholine-induced cGMP production.
|
| ln Vivo |
In vivo, Luteolinidin Chloride protects the heart against ischemia/reperfusion injury through preservation of eNOS function and prevention of endothelial dysfunction. The compound demonstrates cardioprotective effects in animal models of myocardial ischemia.
|
| Enzyme Assay |
In vitro enzyme assays typically involve measuring the inhibitory activity of Luteolinidin Chloride against purified CD38, NADPH oxidase, or tyrosinase. For CD38, the compound is incubated with the enzyme and a fluorescent substrate, and the Ki value is determined from kinetic analyses. For tyrosinase, the inhibition of melanin production is assessed spectrophotometrically.
|
| Cell Assay |
In vitro cellular assays evaluate the compound's effects on endothelial function. Human endothelial cells are treated with Luteolinidin Chloride, and eNOS activity, nitric oxide production, and markers of oxidative stress are measured. The compound's ability to preserve endothelial function under ischemic conditions is assessed in cell culture models.
|
| Animal Protocol |
In vivo animal experiments are performed using rat models of myocardial ischemia/reperfusion injury. Luteolinidin Chloride is administered prior to ischemia, and cardiac function is assessed by measuring coronary blood flow, infarct size, and levels of NAD(P)H and cGMP. The compound's cardioprotective effects are evaluated by comparing treated and untreated groups.
|
| ADME/Pharmacokinetics |
Luteolinidin Chloride has a molecular formula of C15H11ClO5 and a molecular weight of 306.7. It is soluble in DMSO at 50 mg/mL (163.03 mM). For in vivo administration, it can be formulated in 10% DMSO and 90% (20% SBE-β-CD in saline). The compound should be stored at 4°C, sealed, away from moisture and light.
|
| Toxicity/Toxicokinetics |
Toxicological data for Luteolinidin Chloride is limited. The compound is a natural product and is generally considered to have a favorable safety profile at researched doses. No significant toxicity has been reported in the available preclinical studies at the concentrations used for cardioprotection.
|
| References | |
| Additional Infomation |
Luteolinidin chloride is an anthocyanin chloride whose cationic counterpart is Luteolinidin. It contains Luteolinidin molecules.
Luteolinidin Chloride is a natural anthocyanidin found in sorghum and other plants. It has demonstrated antioxidant activity and is being studied for its potential in treating cardiovascular diseases. The compound is also known to block melanin production via tyrosinase inhibition. It is available as a research reagent for biochemical assays. |
| Molecular Formula |
C15H11CLO5
|
|---|---|
| Molecular Weight |
306.6978
|
| Exact Mass |
306.03
|
| CAS # |
1154-78-5
|
| PubChem CID |
6451196
|
| Appearance |
Brown to reddish brown solid powder
|
| Density |
1.530 g/mL at 25 °C(lit.)
|
| Boiling Point |
229-230 °C(lit.)
|
| Flash Point |
>230 °F
|
| Index of Refraction |
n20/D 1.4760(lit.)
|
| LogP |
0.207
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
336
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MMAGHFOHXGFQRZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O5.ClH/c16-9-6-12(18)10-2-4-14(20-15(10)7-9)8-1-3-11(17)13(19)5-8;/h1-7H,(H3-,16,17,18,19);1H
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)chromenylium-5,7-diol;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~163.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2605 mL | 16.3026 mL | 32.6052 mL | |
| 5 mM | 0.6521 mL | 3.2605 mL | 6.5210 mL | |
| 10 mM | 0.3261 mL | 1.6303 mL | 3.2605 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
